Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2019 Sep;7(Suppl 6):S190.
doi: 10.21037/atm.2019.07.37.

The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a "transcriptomic compass"?

Melissa Bersanelli  1   2 , Alessio Cortellini  3   4 , Sebastiano Buti  1
Affiliations
Editorial

The way towards tailored treatment for metastatic renal cancer patients in the omics era: are we getting a "transcriptomic compass"?

Melissa Bersanelli et al. Ann Transl Med. 2019 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: S Buti received honoraria as speaker at scientific events and advisory role by Bristol-Myers Squibb (BMS), Pfizer; MSD, Ipsen, Roche, Eli-Lilly, AstraZeneca and Novartis; he also received research funding from Novartis. M Bersanelli received honoraria as speaker at scientific events by Bristol-Myers Squibb (BMS) and Pfizer; as consultant for advisory role by Novartis, Mundipharma, BMS and Pfizer; as medical writer by Mundipharma; she also received research funding from Seqirus, Pfizer, Novartis, BMS and Sanofi. A Cortellini received honoraria as consultant from Bristol-Myers Squibb (BMS).

Comment on

References

    1. Gerlinger M, Horswell S, Larkin J, et al. Genomic architecture and evolution of clear cell renal cell carcinomas defined by multiregion sequencing. Nat Genet 2014;46:225-33. 10.1038/ng.2891 - DOI - PMC - PubMed
    1. Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883-92. 10.1056/NEJMoa1113205 - DOI - PMC - PubMed
    1. Crusz SM, Tang YZ, Sarker SJ, et al. Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma. BMC Med 2016;14:185. 10.1186/s12916-016-0729-9 - DOI - PMC - PubMed
    1. Sanfrancesco JM, Cheng L. Complexity of the genomic landscape of renal cell carcinoma: Implications for targeted therapy and precision immuno-oncology. Crit Rev Oncol Hematol 2017;119:23-8. 10.1016/j.critrevonc.2017.09.011 - DOI - PubMed
    1. Turajlic S, Xu H, Litchfield K, et al. Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal. Cell 2018;173:595-610.e11. 10.1016/j.cell.2018.03.043 - DOI - PMC - PubMed